Member access

4-Traders Homepage  >  Shares  >  Euronext Alternext  >  NEOVACS    ALNEV   FR0004032746

NEOVACS (ALNEV)

318
Delayed Quote. Delayed Euronext Alternext - 09/19 11:35:00 am
3.61 EUR   -1.63%
3d ago NEOVACS : 2014 half-year results (DGAP News)
3d ago NEOVACS : 2014 half-year results
06/19 NEOVACS : Miguel Sieler Head of Neovacs: "We develop a groundbreaking techn..
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
09/15/2014 09/16/2014 09/17/2014 09/18/2014 09/19/2014 Date
3.96(c) 3.75(c) 3.87(c) 3.67(c) 3.61(c) Last
886 018 295 238 136 932 404 586 203 253 Volume
+8.20% -5.30% +3.20% -5.17% -1.63% Change
More quotes
Company
Neovacs SA is a biotechnology company.It focuses on an active immunotherapy technology platform with applications in the treatment of autoimmune and inflammatory diseases and cancer.It focuses on development on two Kinoids: Tumor Necrosis Factor-Kinoid and Interferon-Kinoid.The Tumor Necrosis... 
Surperformance© rating of NEOVACS
Trading Rating : Investor Rating :
More about the company
Chart NEOVACS
Duration : Period :
NEOVACS Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 0,50 M
EBIT 2014 -8,95 M
Net income 2014 -7,66 M
Debt 2014 3,40 M
Yield 2014 -
Sales 2015 110 M
EBIT 2015 33,6 M
Net income 2015 37,7 M
Debt 2015 76,0 M
Yield 2015 -
PER 2014 -
PER 2015 1,04
EV / Sales 2014 151x
EV / Sales 2015 1,35x
Capitalization 72,3 M
More Financials
Latest news on NEOVACS
3d ago NEOVACS : 2014 half-year results (DGAP News)
3d ago NEOVACS : 2014 half-year results
06/19 NEOVACS : Miguel Sieler Head of Neovacs: "We develop a groundbreaking technology..
06/03 NEOVACS : NAMES NATHALIE THOMAS-PUJOL HEAD OF REGULATORY AFFAIRS (DGAP News)
06/03 NEOVACS : names Nathalie Thomas-Pujol as head of Regulatory Affairs
05/20 NEOVACS : to present additional data on SLE treatment at EULAR 2014
05/15 NEOVACS : to present additional data on SLE treatment at EULAR 2014
05/06 NEOVACS : signs strategic sourcing agreement to supply IFNa for phase IIb lupus ..
04/07 NEOVACS : Completes Enrollment for Phase IIB of TNF-Kinoid in Rheumatoid Arthrit..
03/27 NEOVACS : Financial results for 2013
03/27 NEOVACS : Financial Results for 2013
03/12 NEOVACS : announces positive iDSMB review of the phase IIb study of TNF-Kinoid i..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
NEOVACS : Income Statement Evolution
More Financials
EPS Revisions
NEOVACS : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF